Top Story
- Medical Affairs
US lawmakers have raised alarms about BGI, a major Chinese genomics firm, allegedly attempting to skirt regulatory oversight and potential political backlash by creating subsidiaries in the United States. Representatives Mike Gallagher and Raja Krishnamoorthi have specifically requested the inclusion of BGI's subsidiaries, Innomics and STOmics, [...]
Latest Stories
- Artificial Intelligence
- Data Analytics & Syndicated Reports
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
ASLAN Pharmaceuticals Limited ASLN date announcement
ASLAN Pharmaceuticals Limited now has four catalyst announcements on the calendar after revealing the date on which they will release trial results for Eblasakimab (ASLAN004) - (TREK-DX). Now that the Phase 2b trial is completed, [...]
Read MoreYS Biopharma Co. Ltd. YS earnings announcement
YS Biopharma Co. Ltd. fell in line with their revenue estimate but fell short of their EPS estimate, according to their recent quarterly earnings data. EPS was -$0.12, missing estimates by [...]
Read MoreVertex Pharmaceuticals Incorporated VRTX date announcement
Vertex Pharmaceuticals Incorporated, makers of Suzetrigine (VX-548), will be announcing their top-line results for the drug's recent NDA Filing trial on August 31, 2024. Our calculations show a 70.7% chance that the drug makes [...]
Read MoreImmutep Limited IMMP results announcement
Immutep Limited released new information about their Phase 1 trial for IMP761. Our analysts provided the following summary:
"Trial planned for mid-2024."
This is one of three upcoming announcements for the company.
The market was [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest